A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry
Ver/ abrir
Use este enlace para citar
http://hdl.handle.net/2183/29406
A non ser que se indique outra cousa, a licenza do ítem descríbese como Atribución-NoComercial-SinDerivadas 3.0 España
Coleccións
- INIBIC-ICATC - Artigos [156]
Metadatos
Mostrar o rexistro completo do ítemTítulo
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term RegistryAutor(es)
Data
2021-12-27Cita bibliográfica
Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail [Internet]. 2021 Dec 27. Online ahead of print
Resumo
[Abstract] Aims: To perform a comprehensive characterization of acute heart failure (AHF) with preserved (HFpEF), versus mildly reduced (HFmrEF) versus reduced ejection fraction (HFrEF).
Methods and results: Of 5951 participants in the ESC HF Long-Term Registry hospitalized for AHF (acute coronary syndromes excluded), 29% had HFpEF, 18% HFmrEF, and 53% HFrEF. Hospitalization reasons were most commonly atrial fibrillation (more in HFmrEF and HFpEF), followed by ischaemia (HFmrEF), infection (HFmrEF and HFpEF), worsening renal function (HFrEF), and uncontrolled hypertension (HFmrEF and HFpEF). Hospitalization characteristics included lower blood pressure, more oedema and higher natriuretic peptides with lower ejection fraction, similar pulmonary congestion, more mitral regurgitation in HFrEF and HFmrEF and more tricuspid regurgitation in HFrEF. In-hospital mortality was 3.4% in HFrEF, 2.1% in HFmrEF and 2.2% in HFpEF. Intravenous diuretic (∼80%) and nitrate (∼15%) use was similar but inotrope use greater in HFrEF (16%, vs. HFmrEF 7.4% vs. HFpEF 5.3%). Weight loss and estimated glomerular filtration rate improvement were greater in HFrEF, whereas reduction in natriuretic peptides was similar. Over 1 year post-discharge, events per 100 patient-years (95% confidence interval) in HFrEF versus HFmrEF versus HFpEF were: all-cause death 22 (20-24) versus 17 (14-20) versus 17 (15-20); cardiovascular (CV) death 12 (10-13) versus 8.6 (6.6-11) versus 8.4 (6.9-10); non-CV death 2.4 (1.8-3.1) versus 3.3 (2.1-4.8) versus 4.5 (3.5-5.9); all-cause hospitalization 48 (45-51) versus 35 (31-40) versus 42 (39-46); HF hospitalization 29 (27-32) versus 19 (16-22) versus 17 (15-20); and non-CV hospitalization 7.7 (6.6-8.9) versus 9.6 (7.5-12) versus 15 (13-17).
Conclusion: In AHF, HFrEF is more severe and has greater in-hospital mortality. Post-discharge, HFrEF has greater CV risk, HFpEF greater non-CV risk, and HFmrEF lower overall risk.
Palabras chave
Heart failure with mid-range ejection fraction
Heart failure with mildly reduced ejection fraction
Heart failure with preserved ejection fraction
Hospitalization
Prognosis
Treatment
Heart failure with mildly reduced ejection fraction
Heart failure with preserved ejection fraction
Hospitalization
Prognosis
Treatment
Versión do editor
Dereitos
Atribución-NoComercial-SinDerivadas 3.0 España
ISSN
1388-9842
Ítems relacionados
Mostrando ítems relacionados por Título, autor ou materia.
-
Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes – from the ESC-HFA EORP Heart Failure Long-Term Registry
Kaplon-Cieslicka, Agnieszka; Benson, Lina; Chioncel, Ovidiu; Crespo-Leiro, María Generosa; Coats, Andrew J.S.; Anker, Stefan; Ruschitzka, Frank; Hage, Camilla; Drozdz, Jaroslaw; Seferovic, Petar; Rosano, Giuseppe; Piepoli, Massimo; Mebazaa, Alexandre; McDonagh, Theresa; Lainscak, Mitja; Savarese, Gianluigi; Ferrari, Roberto; Mullens, Wilfried; Bayes-Genis, Antoni; Maggioni, Aldo P.; Lund, Lars H. (European Society of Cardiology, 2023-04-27)[Abstract] Aims: To comprehensively assess hyponatraemia in acute heart failure (AHF) regarding prevalence, associations, hospital course, and post-discharge outcomes. Methods and results: Of 8298 patients in the European ... -
Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
Kapelios, Chris J.; Benson, Lina; Crespo-Leiro, María Generosa; Anker, Stefan; Coats, Andrew J.S.; Chioncel, Ovidiu; Filippatos, Gerasimos; Lainscak, Mitja; McDonagh, Theresa; Mebazaa, Alexandre; Metra, Marco; Piepoli, Massimo F.; Rosano, Giuseppe M.C.; Ruschitzka, Frank; Savarese, Gianluigi; Seferovic, Petar M.; Volterrani, Maurizio; Maggioni, Aldo P.; Lund, Lars H. (2023-03-04) -
Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry
Bonapace, Stefano; Rossi, Andrea; Laroche, Cécile; Crespo-Leiro, María Generosa; Piepoli, Massimo F.; Coats, Andrew J. S.; Dahlström, Ulf; Malek, Filip; Macarie, Cezar; Temporelli, Pier Luigi; Maggioni, Aldo P.; Tavazzi, Luigi (Willey Online Library, 2019-12-09)[Abstract] Aims To investigate the still uncertain independent prognostic impact of pulse pressure (PP) in acute heart failure (HF), in particular across the left ventricular ejection fraction (EF) phenotypes, and the ...